Human papillomavirus types in women with invasive cervical carcinoma by HIV status in Kenya

摘要: To evaluate the fraction of invasive cervical carcinoma (ICC) that could be prevented in HIV-infected women by vaccines currently available against human papillomavirus (HPV)16 and 18, we conducted a cross-sectional study with ICC Nairobi, Kenya. Fifty-one HIV-positive were frequency-matched age to 153 HIV-negative women. Cervical cells tested for HPV DNA using polymerase chain reaction-based assays (SPF10-INNO-LiPA). Comparisons adjusted multiplicity types. As expected, multiple-type infections much more frequent (37.2%) than (13.7%) women, but distribution types was similar. HPV16 detected 41.2% versus 43.8% and/or 18 64.7% 60.1% respectively. The only differences borderline statistical significance an excess HPV52 (19.6% 5.2%) lack HPV45 (7.8% 17.0%) compared We have been able assess unprecedented number ICCs as did not know HIV acquisition, cannot exclude it had occurred too late life affect type involved carcinogenesis. However, if our findings confirmed, they would suggest efficacy current prevent is similar provided vaccination administered before sexual debut, recommended.